1. Market Research
  2. > Biotechnology Market Trends
Global Biopharmaceuticals Market

Global Biopharmaceuticals Market

  • July 2017
  • 203 pages
  • ID: 5023806


Table of Contents

Search Inside

In the year 2015, the global market for biopharmaceuticals was valued at USD 176.9 billion. It is estimated at USD 192.2 million for the year 2016 and is projected to reach USD 291 billion by the year 2021. The estimated CAGR during the forecast period (2016-2021) is 8.6%.

Current trends in biopharmaceuticals market:

On 6th September, Arizona-based company HSRx Biopharmaceutical announced that its orally administered broad-spectrum antiviral drug HSRx 431™ is effective against the Zika virus. They plan to test their claim by conducting human trials in 2017, and if these are found to be successful, they plan to seek accelerated drug approval from the U.S. FDA.

With the patents of most of the conventional blockbuster drugs expiring, biopharmaceuticals are currently being considered the next big thing in pharmaceutical industry.
Biopharmaceuticals currently represent a large segment of product pipelines of most of the major pharmaceutical companies.
More than half of the current top 20 blockbuster drugs are biopharmaceuticals.
Monoclonal antibodies currently own the largest market share in terms of value in the global biopharmaceuticals market. Some of the top-selling monoclonal antibodies include Adalimumab, Infliximab, Rituximab and Bevacizumab.
Vaccines represent the second largest segment in biopharmaceuticals market, followed by monoclonal antibodies. Recently, some of the vaccines also achieved blockbuster status with the introduction of vaccines like Gardasil.
Despite the large market size in terms of value, monoclonal antibodies do not lead the biopharmaceuticals market in terms of volume. Vaccines currently represent the largest market segment in the global biopharmaceuticals market in terms of volume.
Biopharmaceuticals currently represent around 20% of the entire pharmaceutical market revenue. This percentage share of biopharmaceuticals in global pharmaceutical market is only expected to increase in the future.
The revenue from sales of biopharmaceuticals represents the major chunk of the total company revenue for several large companies, such as Novartis, AbbVie and Pfizer etc.
Biopharmaceuticals can be considered as one of the most sophisticated and groundbreaking achievements in modern science. Unlike conventional pharmaceuticals that are synthesized by chemical synthesis, biopharmaceuticals are synthesized through biological synthesis in living systems. Due to their biological origin, the biopharmaceuticals show much greater efficacy and efficiency when compared to conventional pharmaceuticals. Since the biopharmaceuticals act by modulation of physiological processes at a cellular level, they can effectively treat the disorders that conventional pharmaceuticals could not treat.

Biopharmaceuticals are the preferred choice of treatment for biomolecule deficiency disorders like hormone deficiency or growth factor deficiency. They can also be used for stimulating and/or suppressing immune reactions, which makes them an ideal treatment option for autoimmune disorders. The most important contribution of biopharmaceuticals is in the field of targeted drug therapy and the use of biopharmaceuticals is revolutionizing this field.

Market Dynamics

Since biopharmaceuticals can technically modulate any physiological pathway that has been fully understood, there is a huge growth potential for the biopharmaceuticals market.


As a result of the huge advantages that biopharmaceuticals offer over conventional medicines, their use is continuously increasing. This, combined with the ability of biopharmaceuticals to treat diseases that were previously untreatable, has resulted in a huge market demand, which in turn has increased the profit margins for manufacturers. All these factors together are driving the biopharmaceuticals market.


Factors like complicated and cumbersome regulatory requirements, high-end manufacturing requirements and continuously increasing demand for affordable biopharmaceuticals (which is not possible due to huge development and manufacturing costs) are hindering the market growth.


Currently, the biopharmaceuticals market has great opportunities for both new market entrants and existing players. The patents for several biopharmaceuticals are expiring in the next five years and this creates an opportunity for biosimilars manufacturers. Similarly, no company has yet found a way to effectively reduce the cost of biosimilars and there is a huge market opportunity for any company that can solve this problem.


Despite many growth factors driving the biopharmaceuticals market, the market faces severe challenges. These need to be overcome in order to tap the full potential of this market. One such factor is the requirement of cold storage for almost all the biopharmaceuticals. This limits their reach in the developing and third world countries. In addition, the process of developing a biopharmaceutical is also extremely difficult, as it involves living biological systems. This also limits the scalability, as scaling a biological system is different from scaling an equipment-based system.

The current biopharmaceutical products pan across several therapeutic areas and product classes. Based on this, the biopharmaceutical market can be segmented into products and therapeutic area. Based on the product, the biopharmaceuticals market can be segmented into monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, synthetic immunomodulators, vaccines and recombinant enzymes, among others. Among these, the monoclonal antibodies happen to be the largest market segment with 37.31% share in the year 2015.

Based on the therapeutic area/application, the biopharmaceuticals market can be segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, hormonal disorders, disease prevention, cardiovascular diseases, neurological diseases and other diseases. Among these, oncology happens to be the largest segment with 30.5% share in the year 2015.

Geographically, the biopharmaceuticals market can be segmented into North America (United States, Canada and Mexico), Europe (The United Kingdom, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (Japan, China, Australia, South Korea, India and Rest of Asia-Pacific), Middle East & Africa (Gulf Cooperation Council Countries, South Africa and Rest of Middle East & Africa) and South America (Brazil, Argentina and Rest of South America). Among these, North America was found to be the largest market shareholder with 44.5% of the share in the year 2015.

Due to the huge profit margins and growth prospects, biopharmaceuticals have garnered the attention of several large drug development companies. Some of the key players in the market are:

Abbott Laboratories
Biogen Inc.
Bristol-Myers Squibb
Eli Lilly & Company
Pfizer Inc.
Roche Holding AG
Sanofi Aventis

What the report offers/b>

Market analysis for the global biopharmaceuticals market, with region-specific assessments and competition analysis.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the global biopharmaceuticals market.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is blooming and the regions that are still untapped.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Single-use Bioreactors Market by Product, Type of Molecule, Type of Cell, Application, End User - Global Forecast to 2022

Single-use Bioreactors Market: Global Forecast until 2022

  • $ 5650
  • Industry report
  • November 2017
  • by MarketsandMarkets

The single-use bioreactors market is projected to grow at a CAGR of 21.9%.The single-use bioreactors market is expected to reach 2,685.1 million by 2022 from USD 997.6 million in 2017 at a CAGR of 21.9%. ...

The 2019-2024 World Outlook for Biopharmaceutical Bioseparation Systems

The 2019-2024 World Outlook for Biopharmaceutical Bioseparation Systems

  • $ 995
  • Industry report
  • January 2018
  • by ICON Group

This study covers the world outlook for biopharmaceutical bioseparation systems across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry ...

The 2019-2024 World Outlook for Biopharmaceuticals

The 2019-2024 World Outlook for Biopharmaceuticals

  • $ 995
  • Industry report
  • January 2018
  • by ICON Group

This study covers the world outlook for biopharmaceuticals across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), fo ...


Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on